 |
市场调查报告书
商品编码
1988558
分子即时检测 (mPOC) 市场展望与创新 - 第 11 版 (2025-2030)Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 11th Edition (2025 to 2030) |
||||||
分子即时检测 (mPOC) 透过将分子诊断的准确性更便捷地应用于患者，持续革新诊断流程。在 "分子即时检测 (mPOC) 市场展望与创新 - 第 11 版 (2025-2030)" 报告中，Kalorama Information 分析了过去十年间已显着成熟但仍充满活力的 mPOC 市场。儘管真正的即时检测与床边分子检测之间的区别并非总是泾渭分明，但 Kalorama 将 mPOC 的核心价值定义为：小型便携式诊断设备能够快速提供检测结果，使分子检测在医生诊室和其他分散环境中切实可行。
本报告的主要内容
本报告对全球分子即时检测市场进行了全面评估，涵盖以下内容：
- 系统及耗材市场估算及预测（截至2030年）
- 依地区、疾病领域和公司划分的市场细分
- 对真正的分子即时检测系统和更广泛的近专利分子检测市场的分析
- 基于一手和二手研究的市场和产品层面的收入估算
研究资料包括公司揭露资讯、政府出版物、行业期刊、商业媒体、分析师报告、法律文件以及对製造商、检测实验室和行业专家的访谈。所有市场价值均以当前美元计价，并以 2025 年为基准年计算。
Kalorama 对分子诊断即时侦测 (mPOC) 的定义
本报告主要区分以下两个市场区隔：
- 真正的分子诊断即时检测系统：占地面积小，能够快速提供检测结果，并且已获得或可能在不久的将来获得 CLIA 豁免资格的系统。
- 患者近场分子检测系统：包括支援在分散式环境中进行中等至高度复杂检测的大型或模组化平台。
主要应用与成长机会
传统上，mPOC 系统在呼吸系统检测方面最为成功，而 COVID-19 疫情进一步加剧了这一趋势。该细分市场对价格仍然十分敏感，并面临来自免疫分析的激烈竞争，本报告指出了进一步的成长机会。
近期快速PCR检测和用于分子诊断的家用检测的获批，进一步扩大了目标市场，并提高了mPOC技术的临床应用价值。
目录
第一章 摘要整理
- 关于研究机构
- 研究范围与方法
- mPOC 市场概览
- 定义真正的分子级即时侦测
- 定义床边分子即时侦测
- 2026 年分子诊断即时检测的现状
- 真正的 mPOC 系统
- "床边" 分子系统市场
- mPOC 市场趋势与发展
- 分子即时侦测的应用
- 主要 mPOC 平台
- 趋势
第二章 分子级即时检测的发展与趋势市场
- 分子即时检测与新冠肺炎
- 美国疾管中心的初步因应措施及长期情势
- 新冠肺炎特有的挑战
- 生物医学高级研究与发展局指导分子即时检测的资金投入
- 监理趋势
- 联盟、资金和奖励
- 销售
- 分子诊断即时侦测的优点与缺点
- 论证：敏感度/特异性理论
- 新系统及侦测项目扩展
- 新系统引进及发展
- 联合检测市场的变化：SARS-CoV-2、甲型流感、乙型流感和呼吸道合胞病毒
- 性传染感染持续成长
- 与分子即时检测相关的交易与投资系统
- 罗氏与Sapphiros的供应与生产协议
- Cepheid与Oxford Nanopore的合作
- 罗氏收购Lumira Dx
- 赛默飞世尔科技收购Mesa Biotech
- 将中国视为即时检测市场
- 即时诊断中常用的检测项目与分析物
- 分子即时诊断的组成技术
- 微流控技术
- 定量PCR (qPCR)
- 微阵列
- 等温扩增
- 测试自动化
- 引子和探针
- 侦测
- 分子诊断
- 实时PCR (qPCR)
- 等温扩增法
- 线性探针侦测
- 次世代定序
- 应用及潜力分子即时侦测 (POC) 目前应用实例
- 分子即时检测 (POC) 诊断的关键检测领域
- 流感
- 快速诊断侦测 (RIDT) 重新分类
- 院内感染 (HAI)
- A链球菌
- 呼吸道合胞病毒 (RSV)
- 新兴应用领域
- 寨卡病毒
- 其他呼吸道感染
- B群链球菌
- 人类乳突病毒
- 单纯疱疹病毒
- 阴道炎
- 结核病
- 疟疾
- 其他热带疾病和被忽视的热带疾病
- 癌症
- 欧洲医疗器材法规
第三章 mPOC 市场分析
- 分子即时检测市场分析
- 市场假设与结论
- 区域占有率
- 细分市场
- 床边分子诊断市场
- 床边市占率
第四章 公司简介
- Abbott Laboratories
- Aidian Oy
- Akonni Biosystems
- binx health, inc.
- Biocartis NV
- bioMerieux SA
- Cepheid (Danaher)
- 分子生物学医疗保健相关感染 (HAI) 检测
- 分子层面性传染感染及妇科检测
- 分子生物学重要感染检测
- 分子肿瘤学/基因检测
- Credo Diagnostics Biomedical Pte. Ltd.
- Curetis NV (OpGen)
- DiaSorin S.p.A
- GenMark Diagnostics (Roche)
- Greiner Bio-One GmbH
- Meridian Bioscience, Inc. (SD Biosensor)
- Mesa Biotech, Inc. (Thermo)
- Sherlock Biosciences
- QIAGEN NV
- QuantuMDx Group
- QuidelOrtho Corporation
- Roche
- Sekisui Diagnostics LLC
Molecular point-of-care testing continues to reshape diagnostic workflows by bringing the accuracy of molecular methods closer to the patient. In Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 11th Edition (2025 to 2030), Kalorama Information examines a market that has matured significantly over the past decade while remaining dynamic. Distinctions between true point-of-care and near patient molecular testing are not always clear, but Kalorama defines the core value of mPOC as smaller, portable diagnostic devices that answer workflows with rapid turnaround times that make molecular testing practical in physician offices and other decentralized settings.
What This Report Covers
This report provides a comprehensive assessment of the global molecular point-of-care market, with coverage that includes:
- Market estimates and forecasts for systems and consumables through 2030
- Segmentation by region, disease area, and company
- Analysis of both true molecular point-of-care systems and the broader near patient molecular market
- Market and product level revenue estimates supported by primary and secondary research
Research inputs include company disclosures, government publications, trade journals, business press, analyst reports, legal filings, and interviews with manufacturers, laboratories, and industry experts. All market values are expressed in current U.S. dollars and reflect base year sales for 2025.
How Kalorama Defines Molecular Point-of-Care
The report distinguishes between two primary market segments:
- True molecular point-of-care systems, characterized by small footprints, rapid turnaround times, and CLIA waived status or near term waiver potential
- Near patient molecular systems, which include larger or modular platforms that support moderate or high complexity testing in decentralized settings
Key Applications and Growth Opportunities
Historically, mPOC systems have been most successful in respiratory testing, a trend reinforced by COVID-19. While this segment remains price sensitive and competitive with immunoassays, the report identifies additional growth opportunities.
Recent approvals of rapid PCR and molecular home tests have further expanded the addressable market and reinforced the clinical relevance of mPOC technologies.
Table of Contents
Chapter 1: Executive Summary
- About Kalorama Information
- Scope and Methodology
- mPOC Market Overview
- Defining True Molecular Point-of-Care
- Defining Near-Patient Molecular POC
- Where Is Molecular Point-of-Care in 2026?
- True mPOC Systems
- Table 1-1: Global Molecular Point-of-Care Market, 2025-2030 ($ million)
- "Near-Patient" Molecular Systems Market
- Table 1-2: Global Near Patient Molecular Systems Market, 2025-2030 ($ million)
- mPOC Market Observations and Trends
- True mPOC Systems
- Usage of Molecular Point-of-Care
- Leading mPOC Platforms
- Table 1-3: Molecular POC Diagnostic Platforms and Technologies
- Trends
Chapter 2: Molecular Point-of-Care Market Development and Trends
- Molecular POC and COVID-19
- Table 2-1: Molecular POC COVID-19 Tests and Regulatory Status
- CDC Initial Response, Long Term Situation
- COVID-19's Unique Challenge
- BARDA Directs Funding to mPO
- Regulatory Developments
- Consortia, Funding, Prizes
- Deals
- Table 2-2: Deals in Molecular Point-of-Care, April 2019-December 2025
- Advantages and Disadvantages of Molecular Point-of-Care
- Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
- Justification: The Sensitivity/Specificity Argument
- New Systems and Menu Expansion
- New Systems Introduced, in Development
- Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
- STI Continues to Be a Growth Area
- Deals, Investment in mPOC Systems
- Roche's Supply and Manufacturing Agreement with Sapphiros
- Cepheid's Partnership with Oxford Nanopore
- Roche Acquires LumiraDx
- Thermo Acquires Mesa Biotech
- China as a POC Market
- Common Tests and Analytes in POC Diagnostics
- Component Technologies of Molecular Point-of-Care Diagnostics
- Microfluidics
- Quantitative PCR (qPCR)
- Microarrays
- Isothermal Amplification
- Test Automation
- Primers and Probes
- Detection
- Molecular Diagnostics
- Real-Time PCR (qPCR)
- Isothermal Amplification Methods
- Line Probe Assays
- Next-Generation Sequencing
- Applications and Potential Applications for Molecular Point-of-Care
- Major Testing Areas for Molecular POC Diagnostics
- Influenza
- Reclassification of RIDTs
- Hospital-Acquired Infections (HAIs)
- Strep A
- Respiratory Syncytial Virus (RSV)
- Emerging Applications
- Zika
- Other Respiratory Infections
- Group B Streptococcus
- Human Papillomavirus
- Herpes Simplex Virus
- Vaginitis
- Tuberculosis
- Malaria
- Other Tropical and Neglected Diseases
- Cancer
- European Device Regulations
Chapter 3: mPOC Market Analysis
- Molecular Point-of-Care Market Analysis
- Table 3-1: Global Molecular Point-of-Care Market, 2025-2030 ($ million)
- Figure 3-1: Global Molecular Point-of-Care Market, 2025-2030 ($ million)
- Market Assumptions and Conclusions
- Regional Shares
- Table 3-2: Geographic Breakout of the Molecular Point-of-Care (mPOC) Market, by Region, 2025 ($ million) [APAC, Europe, North America, Rest of World]
- Segment Breakout
- Figure 3-2: Global True mPOC Market, by Disease Indication, 2025 (%) [Respiratory, Other]
- "Near Patient Molecular" Market
- Table 3-3: Global Near Patient Molecular Systems Market, 2025-2030 ($ million)
- Figure 3-3: Global Near Patient Molecular Systems Market, 2025-2030 ($ million)
- Figure 3-4: Global Near Patient mPOC Market Share, by Segment, 2025 (%) [Respiratory/COVID, STI/Women's Health, Other]
- Figure 3-5: Global Respiratory Near Patient mPOC Market Share, by Test Type, 2025 (%) [Combo/Syndromic, Single Pathogen]
- Market Share Near Patient
- Figure 3-6: Near Patient Molecular Testing Market Share, by Vendor, 2025 (%)
Chapter 4: Company Profiles
- Abbott Laboratories
- Aidian Oy
- Akonni Biosystems
- binx health, inc.
- Biocartis NV
- bioMerieux SA
- Table 4-1: FilmArray and SpotFire Est. Systems Installed per Quarter, Q4 2018-Q3 2025
- Figure 4-1: FilmArray and SpotFire Est. Systems Installed by Quarter, Q4 2018-Q3 2025
- Figure 4-2: bioMerieux Molecular Biology Revenues by Quarter, Q1 2016-Q3 2025
- Cepheid (Danaher)
- Molecular Healthcare-Acquired Infection (HAI) Testing
- Molecular Sexual Health and Women's Health Testing
- Molecular Critical Infectious Disease Testing
- Molecular Oncology/Genetics Testing
- Credo Diagnostics Biomedical Pte. Ltd.
- Curetis NV (OpGen)
- DiaSorin S.p.A
- GenMark Diagnostics (Roche)
- Greiner Bio-One GmbH
- Meridian Bioscience, Inc. (SD Biosensor)
- Mesa Biotech, Inc. (Thermo)
- Sherlock Biosciences
- QIAGEN NV
- QuantuMDx Group
- QuidelOrtho Corporation
- Roche
- Sekisui Diagnostics LLC
2026年全球即时分子诊断市场报告
即时分子诊断市场－全球产业规模、份额、趋势、机会及预测（依技术、应用、检测地点、最终用户、地区及竞争格局划分，2021-2031年）
全球贫血诊断解决方案市场（按产品类型、技术、分销管道、应用和最终用户划分）预测（2026-2032年）
全球照护现场诊断市场（按产品/服务、技术、样本类型、应用和最终用户划分）- 预测至 2030 年按产品类型、技术、应用和最终用户照护现场诊断分子诊断市场 - 全球预测 2025-2030
照护现场诊断分子诊断市场规模、份额和趋势分析报告：按应用、技术、测试地点、最终用途、地区和细分市场预测，2025 年至 2033 年美国即时诊断分子诊断市场规模、份额和趋势分析报告：按技术、应用、检测地点、最终用途和细分市场预测，2025 年至 2033 年
2025 年至 2033 年即时诊断分子诊断市场报告（按产品与服务、技术、应用、最终用户和地区划分）
POC 分子诊断的全球市场 2024-2028
北美传染病即时护理分子检测市场规模及预测（2021-2031）、区域份额、趋势和成长机会分析报告